Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients

International Journal of Hematology

Volumn 81, Issue 4, 2005, Pages 349-351

  Lin, Peng Chan ^a   Poh, Say Bee ^a   Lee, Ming Yang ^a   Hsiao, Liang Tsai ^a   Chen, Po Min ^a   Chiou, Tzeon Jye ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Hematopoietic stem cell transplantation; Hepatitis B virus reactivation; Lamivudine

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; LAMIVUDINE; PREDNISONE; VINCRISTINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; ACUTE DISEASE; FATALITY; LIVER FAILURE;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HUMANS; LAMIVUDINE; LEUKEMIA, MYELOID; LIVER FAILURE, ACUTE; LYMPHOMA, NON-HODGKIN; MALE;

EID: 22844433169     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.A10411     Document Type: Article

References (10)

1. Strasser SI, McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood. 1999;93:1127-1136.
2. Endo T, Sakai T, Fujimoto K, et al. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2001;27:433-436.
3. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002;100:391-396.
4. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-1749.
5. Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003; 44:1281-1285.
6. Reimer P, Kunzmann V, Wilhelm M, et al. Cellular and humoral immune reconstitution after autologous peripheral blood stem cell transplantation (PBSCT). Ann Hematol. 2003;82:263-270.
7. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702-709.
8. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation. 2004;77:859-864.
9. Chiba T, Yokosuka O, Goto S, et al. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. Eur J Haematol. 2003;71:220-223.
10. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90.